Formycon (FYB) Company presentation summary

Company overview and mission

• Established in 2012 in Munich, focused exclusively on biosimilars with a business model based on success share and royalty streams.

• Employs 200 people from over 27 countries, with more than 80% engaged in R&D.

• Mission centers on improving patient access to vital medicines and easing financial strains on healthcare systems.

Strategic growth levers and market opportunity

• Growth strategy leverages geographic diversification, a balanced portfolio, scientific excellence, and lean development.

• 39 blockbuster drugs with over $190 billion in global sales are losing exclusivity by 2032, creating significant biosimilar opportunities.

• Biosimilars represent the fastest-growing segment in pharma, with the US market showing a 97% CAGR from 2015-2021.

Product pipeline and commercialization

• Portfolio includes three approved biosimilars (Lucentis, Stelara, Eylea) and four candidates (Keytruda, Dupixent, and two undisclosed immunology assets).

• Lucentis biosimilar launched in 24 countries; Stelara and Eylea biosimilars launched in US, EU, and other key markets.

• Keytruda biosimilar candidate completed patient enrollment, with positive data and partnerships in MENA, US, Canada, and APAC; market launch expected after 2029.

• Dupixent biosimilar candidate achieved technical proof of similarity, with partnering activities starting in 2026.